A Phase II Study the Evaluate the Effects of Cabozantinib in Patients with Unresectable/Metastatic Adrenocortical Carcinoma
MD Anderson Study Status
This phase II trial studies how well cabozantinib works in treating patients with adrenal cortex cancer that has spread to nearby tissue, lymph nodes (locally advanced), or other places in the body (metastatic), and cannot be removed by surgery (unresectable). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Metastatic Carcinoma in the Adrenal Cortex, Stage III Adrenal Cortex Carcinoma AJCC v8, Stage IV Adrenal Cortex Carcinoma AJCC v8, Unresectable Adrenal Cortex Carcinoma
Endocrine Neoplasia and Hormone Disorders
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.